The founders and directors of cannabis play Zelda Therapeutics have committed to holding on to their shares as a show of faith in the company, as almost 30 per cent of the shares come out of escrow.
Escrow typically refers to shares that are held by founders, early investors or directors who are restricted from selling for a period of one to two years. Their release from escrow can have a big impact on a company’s share price.
Medicinal cannabis biotech Zelda (ASX:ZLD) has 224.4 million shares hitting the market on November 22, which makes up about 29 per cent of the company’s issued total.
But the medicinal cannabis developer today moved to reassure shareholders, saying directors and founders Harry Karelis, Dr Stewart Washer, Mara Gordon and Jason Peterson would not sell any shares they own or control for the next year — unless it helped on-board a significant investor.
“The commitment has been entered into by the founders to clearly demonstrate their true belief in the company’s future and business plan,” the ASX release stated.
Mr Karelis said a voluntary extension of the escrow period demonstrated the founders were in it for the long haul.
“Since founding the company in 2015, the Founders have worked hard to position Zelda at the forefront of the burgeoning global medicinal cannabis industry,” he said.
“We have established a number of collaborations with globally recognised institutions and commenced our clinical trial activities. We are excited by the potential for company transformational milestones being achieved over the next year.”
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.